Interview with Rafael Martau, Commercial Director, Bomi Farma
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ CEP: 22713-010,Brazil
Tel: (21) 2159-2600
Laboratórios Bagó do Brasil is a pharmaceutical company outlined by its competencies of innovation and vision of the future. The company is an important part of Bagó Group founded in 1934, in Argentina. Established in the country in 2002, its founders have created an organization with a solid reputation based on ethics and commitment to quality.
The slogan “Ethics at the service of Heath” holds an special place on guiding the company’s actions, and so does the premium, the priority ingredient of the organization’s roles.
With a head office and a plant in the city of Rio de Janeiro, a distribution center in Brasilia and representatives in the major centers of consumption in the country, the company develops, distributes and commercializes innovative pharmaceutical products.
With an excellence and reliability standing, the company progressively attracts more attention and the trustiness of the country’s medical class, acquiring the respect of Brazilian’s consumers.
Keflex
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
What have been some of the recent milestones and achievements contributing to AstraZeneca Brazil’s status as the country’s fastest growing MNC? What happened in the last 10 years was a…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
10 days ago, your Swedish counterpart Mats Larsson made a technical visit here at ANVISA and said he had a lot to learn. What is it about ANVISA that can…
Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
See our Cookie Privacy Policy Here